Latest Funding News

Endeavour Group’s FY26 results show modest sales growth but a sharp profit decline due to $372 million in significant item expenses, alongside a strategic reset and climate commitments.

Adore Beauty delivered record FY26 revenue of $207.3 million, driven by retail expansion and owned brands, while posting a statutory loss amid heavy investment. The Group targets 10%+ revenue growth and a sharp EBITDA increase in FY27 as its omni-channel strategy matures.

Stanmore Resources maintained steady coal production in the first half of 2026 while boosting earnings and completing a corporate debt refinancing that enhances financial flexibility.

PLS Group Limited delivered a robust FY26 with record lithium production, strong cash flow, and progress on key expansions including the Ngungaju Plant restart and P2000 feasibility study.

Liberty Financial Group delivered a 7.8% rise in net profit after tax to $143.8 million for FY26, underpinned by record loan originations and stable credit quality. The group declared a fully franked 15 cent special dividend payable in September 2026.

Ansell Limited (ASX:ANN) reported a robust FY26 with net profit doubling to US$208.6 million, driven by strong sales growth and operational resilience amid geopolitical challenges. The company also announced a leadership change and reaffirmed its sustainability ambitions.

Property for Industry Limited (NZX: PFI) reported a resilient FY26, delivering a 14% rise in adjusted funds from operations per share and a 10.5% dividend increase, backed by strong portfolio occupancy and progress in green developments.

Cash Converters posted 11% revenue growth in FY26 driven by franchise acquisitions and loan book evolution, while net profit fell 20% amid strategic shifts and one-off costs.

BCAL Diagnostics has updated investors on its $10 million convertible note facility, revealing $7.6 million drawn to date with further funding contingent on upcoming shareholder approval.

Gryphon Capital Income Trust (ASX: GCI) posted a 31% increase in revenue and a 30.6% jump in profit for the year ended 30 June 2026, underpinned by significant capital raises and expanded investment in Australian RMBS and ABS portfolios.

AdAlta Limited (ASX:1AD) has progressed its ‘East to West’ cellular immunotherapy strategy by securing its first CAR-T asset, advancing Australian manufacturing and US FDA regulatory engagement, while raising A$5.3 million in FY2026 and reporting a net loss of $4.68 million.

Qualitas Real Estate Income Fund (ASX: QRI) posted a 6% rise in operating profit to $70.9 million for FY26, driven by portfolio growth and rising interest rates. The Trust raised $34.6 million via an entitlement offer to expand its mortgage-backed loan portfolio, maintaining stable distributions despite a modest unit price discount to NAV.